An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses
作者:Yanmei Hu、Rami Musharrafieh、Chunlong Ma、Jiantao Zhang、Donald F. Smee、William F. DeGrado、Jun Wang
DOI:10.1016/j.antiviral.2017.01.006
日期:2017.4
only had single to sub-micromolar EC50 values against M2-WT- and M2-V27A-containing influenza A viruses in antiviral assays, but also rescued mice from lethal viral infection by either M2-WT- or M2-V27A-containing influenza A viruses. In addition, we report the design of two analogs of compound 3, and one was found to have improved in vitro antiviral activity over compound 3. Collectively, this study represents
金刚烷胺(例如金刚烷胺(1)和金刚乙胺(2))是FDA批准的抗流感药物,其作用是抑制甲型流感病毒的野生型M2质子通道,从而抑制病毒的脱壳。尽管金刚烷已经成功使用了四十年以上,但是由于新出现的耐药性,其功效被削弱了。在有限数量的赋予金刚烷胺抗性的M2突变体中,发现M2-V27A突变体是在药物选择压力下的主要突变体,从而代表了高水平的抗病毒药物靶标。在分子动力学模拟的指导下,我们以前设计了一流的M2-V27A抑制剂。一种有效的先导化合物螺金刚烷胺(3)抑制M2-WT和M2-V27A突变体,IC50值分别为18.7和0.3μM,在体外电生理测定中。受这些发现的鼓舞,在这项研究中,我们进一步检查了化合物3在抑制金刚烷胺敏感和耐药A型流感病毒中的体外和体内抗病毒活性。在抗病毒试验中,化合物3不仅对含M2-WT和M2-V27A的甲型流感病毒具有单微摩尔至亚微摩尔EC50值,而且还使小鼠免于因含M2-W